Results 41 to 50 of about 12,197 (188)

Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro [PDF]

, 2018
Background: Antiretroviral therapy in HIV-positive patients leads to insulin resistance which is central to the pathogenesis of various metabolic abnormalities and cardiovascular disease seen in this patient group. We have investigated the dose–response
David J Back, Adaikalakoteswari, A., Owen, A., Sudeep P Pushpakom, Pushpakom, S.P., Sudhesh Kumar, Andrew Owen, Back, D.J, Tripathi, G, McTernan, P., Owen, Andrew, Pirmohamed, M., Philip McTernan, Pushpakom, S. P., Kumar, S., Tripathi, G., Antonysunil Adaikalakoteswari, Back, D. J., Adaikalakoteswari, A, Pushpakom, S.P, Adaikalakoteswari, Antonysunil, Owen, A, Back, David J, Pirmohamed, Munir, Pushpakom, Sudeep P, Gyanendra Tripathi, McTernan, P, Pirmohamed, M, Back, D.J., Tripathi, Gyanendra, Kumar, Sudhesh, Munir Pirmohamed, McTernan, Philip, McTernan, P. G., Kumar, S   +34 more
core   +1 more source

In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events. [PDF]

PLoS ONE, 2010
Results of the recently published ONTARGET study (The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) showed that telmisartan (80 mg/day) was non-inferior to ramipril (10 mg/day) in reducing cardiovascular events ...
Antonio L Dans, Koon Teo, Peggy Gao, Jyh-Hong Chen, Kim Jae-Hyung, Khalid Yusoff, Suphachai Chaithiraphan, Jun Zhu, Liu Lisheng, Salim Yusuf, Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial Investigators   +10 more
doaj   +1 more source

Effects of telmisartan and olmesartan on insulin sensitivity and renal function in spontaneously hypertensive rats fed a high fat diet

Journal of Pharmacological Sciences, 2016
Although telmisartan, an angiotensin II receptor blocker (ARB), has an agonistic action for proliferator-activated receptor (PPAR)-γ in vitro, it remains to be determined whether telmisartan exerts such an action in vivo using a non-toxic dose (
Hayato Yanagihara, Kentaro Ushijima, Yusuke Arakawa, Ken-ichi Aizawa, Akio Fujimura   +4 more
doaj   +1 more source

Renoprotective effects of telmisartan after unilateral renal ablation in rats [PDF]

, 2013
Tomohiro Matsuo, Yasuyoshi Miyata, Yuji Sagara, Yoshikazu Higami, Shohei Tobu, Manabu Matsuo, Mitsuru Noguchi, Isao Shimokawa, Hiroshi Kanetake, Hideki Sakai Department of Nephro-Urology, Department of Investigative Pathology, Nagasaki University ...
Higami Y, Tobu S, Matsuo, Manabu, Shimokawa, Isao, Noguchi M, Miyata, Yasuyoshi, Sakai, Hideki, Matsuo M, Noguchi, Mitsuru, Kanetake, Hiroshi, Sakai H, Matsuo T, Matsuo, Tomohiro, Tobu, Shohei, Kanetake H, Shimokawa I, Sagara, Yuji, Miyata Y, Sagara Y, Higami, Yoshikazu   +19 more
core   +1 more source

Dialysis-associated hypertension treated with Telmisartan--DiaTel: a pilot, placebo-controlled, cross-over, randomized trial.

PLoS ONE, 2013
UnlabelledTreatment of hypertension in hemodialysis (HD) patients is characterised by lack of evidence for both the blood pressure (BP) target goal and the recommended drug class to use.
Matthias Huber, Till Treutler, Peter Martus, Antje Kurzidim, Reinhold Kreutz, Joachim Beige   +5 more
doaj   +1 more source

TELMISARTAN IN CARDIOVASCULAR RISK REDUCTION [PDF]

, 2018
The article is focused on the issues of clinical efficacy of telmisartan — angiotensin II type 1 receptor blocker from the perspective of its influence on cardiovascular risk in systemic hypertension patients.
О. D. Ostroumova, A. I. Kochetkov, Т. I. Koniev, E. A. Smolyarchuk   +3 more
core   +1 more source

Planning and Evaluation of Bioequivalence Studies of Telmisartan Generic Drug Products

Разработка и регистрация лекарственных средств, 2019
Introduction. Telmisartan is a modern antihypertensive drug, from the group of angiotensin II receptor antagonists, which, recently, has been the purpose of the development and registration of generic drug.
A. L. Khokhlov, D. P. Romodanovsky, A. E. Miroshnikov   +2 more
doaj   +1 more source

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

British Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza, Andrej Belancic, Jens Jordan, Alberto Esteban, Anna Oliveras, Ryan McNally, Panagiota Anyfanti, Jorie Versmissen, María S. Fernández‐Alfonso, Vasilios Kotsis, Thomas Weber, Alexandre Persu, Reinhold Kreutz   +12 more
wiley   +1 more source

Bioequivalence and Food Effect Assessment of Two Fixed‐Dose Combination Formulations of Telmisartan‐Hydrochlorothiazide Tablets in Chinese Healthy Subjects

Clinical and Translational Science
This study assessed the bioequivalence and food effect of two fixed‐dose combination (FDC) formulations of telmisartan‐hydrochlorothiazide tablets (telmisartan 40 mg, hydrochlorothiazide 12.5 mg) in healthy Chinese subjects.
Minwan Hu, Man Yang, Shuyu Zhang, Jiangfan Li, Hongxian Pang, Yingzi Pei, Chao Guo, Xuhong Wang   +7 more
doaj   +1 more source

Therapeutic‐dose verapamil‐induced cardiogenic shock in an older patient: a case report

Journal of Pharmacy Practice and Research, EarlyView.
Abstract Background Calcium channel blocker (CCB) toxicity most commonly follows deliberate overdose. However, severe toxicity at therapeutic doses may occur in susceptible individuals. Severe CCB toxicity often presents with clinical features of bradycardia, hypotension, hyperglycaemia, and lactic acidosis.
Christopher Thuring, Maria Carey, Timothy Webber, Biswadev Mitra   +3 more
wiley   +1 more source